Boenning & Scattergood initiates coverage on Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) with a Market Outperform rating and $31 price target.
This article: 122 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE